KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abbott Laboratories (ABT) Revenue (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Revenue for 17 consecutive years, with $11.5 billion as the latest value for Q4 2025.

  • Quarterly Revenue rose 4.42% to $11.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.3 billion through Dec 2025, up 5.67% year-over-year, with the annual reading at $44.3 billion for FY2025, 5.67% up from the prior year.
  • Revenue hit $11.5 billion in Q4 2025 for Abbott Laboratories, up from $11.4 billion in the prior quarter.
  • In the past five years, Revenue ranged from a high of $11.9 billion in Q1 2022 to a low of $9.7 billion in Q1 2023.
  • Historically, Revenue has averaged $10.7 billion across 5 years, with a median of $10.4 billion in 2021.
  • Biggest five-year swings in Revenue: soared 39.51% in 2021 and later dropped 18.06% in 2023.
  • Year by year, Revenue stood at $11.5 billion in 2021, then dropped by 12.01% to $10.1 billion in 2022, then grew by 1.49% to $10.2 billion in 2023, then rose by 7.16% to $11.0 billion in 2024, then grew by 4.42% to $11.5 billion in 2025.
  • Business Quant data shows Revenue for ABT at $11.5 billion in Q4 2025, $11.4 billion in Q3 2025, and $11.1 billion in Q2 2025.